.
MergerLinks Header Logo

Announced

EQT to acquire a majority stake in Aldevron from TA Associates.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

Pending

Private

Biotechnology

biotechnology company

Friendly

Acquisition

cell and gene therapies

Private Equity

Single Bidder

Synopsis

Edit

EQT agreed to acquire Aldevron, the global supplier of plasmid DNA used in cell and gene therapies from TA Associates. Financial terms were not disclosed. EQT will help advance Aldevron’s R&D and innovation efforts as the company continue to support the rapidly growing field of genetic medicine by providing critical input for the development of new life-saving therapies. "EQT shares our strong values and commitment to excellence and we believe their significant healthcare experience, global presence and industrial network make them an ideal partner as we continue our growth journey,” Michael Chambers, Aldevron Co-Founder and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US